142 related articles for article (PubMed ID: 36455273)
1. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
[TBL] [Abstract][Full Text] [Related]
2. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
[TBL] [Abstract][Full Text] [Related]
4. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
[TBL] [Abstract][Full Text] [Related]
5. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
6. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
Gött H; Uhl E
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
[TBL] [Abstract][Full Text] [Related]
7. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
[TBL] [Abstract][Full Text] [Related]
8. Polymorphous low-grade neuroepithelial tumor of the young with FGFR3-TACC3 fusion mimicking high-grade glioma: case report and series of high-grade correlates.
Golub D; Lynch DG; Pan PC; Liechty B; Slocum C; Bale T; Pisapia DJ; Juthani R
Front Oncol; 2023; 13():1307591. PubMed ID: 38074682
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.
Wang Y; Liang D; Chen J; Chen H; Fan R; Gao Y; Gao Y; Tao R; Zhang H
Oncologist; 2021 Mar; 26(3):173-177. PubMed ID: 32949176
[TBL] [Abstract][Full Text] [Related]
10. Extra-CNS and dural metastases in
Kleinschmidt-DeMasters BK; Gilani A
Neurooncol Pract; 2022 Oct; 9(5):449-455. PubMed ID: 36134017
[TBL] [Abstract][Full Text] [Related]
11. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
12. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
13. Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.
Ballester LY; Moghadamtousi SZ; Leeds NE; Huse JT; Fuller GN
Acta Neuropathol Commun; 2019 Apr; 7(1):63. PubMed ID: 31036092
[No Abstract] [Full Text] [Related]
14. Diffuse Gliomas with
Marastoni E; Mulone D; Barresi V
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730596
[No Abstract] [Full Text] [Related]
15. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
[TBL] [Abstract][Full Text] [Related]
16. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and Molecular Characteristics of
Bae H; Lee B; Hwang S; Lee J; Kim HS; Suh YL
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255255
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma,
Broggi G; Piombino E; Altieri R; Romano C; Certo F; Barbagallo GMV; Vigneri P; Condorelli D; Colarossi L; Colarossi C; Magro G; Tirrò E
Front Neurol; 2022; 13():823015. PubMed ID: 35222252
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
